Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Bladder Cancer: Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma

Research Question:
Which of 3 treatments will work better at treating your type of cancer?

Basic Study Information

Purpose:
If you agree to and are allowed to participate in this study, you will be assigned by 33% chance (a process called randomization similar to rolling a dice) to one of three treatment groups: • Subjects assigned to Treatment Group A, will receive pembrolizumab • Subjects assigned to Treatment Group B, will receive the combination of pembrolizumab and chemotherapy (either cisplatin or carboplatin with gemcitabine). • Subjects assigned to Treatment Group C, will receive chemotherapy (either cisplatin or carboplatin with gemcitabine). Both you and your doctor will know which treatment group you have been assigned to.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02853305?term=3475-361&rank=1
Study Reference #: IGUB-16125

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 275-3351
Email: Park_Bogan@urmc.rochester.edu

Additional Study Details

Return to Search